Transform treatment for immune-mediated diseases, empower people to reimagine their lives.
About Alumis
We are advancing a late-stage portfolio of next-generation targeted therapies to optimize patient outcomes across a wide range of immune-mediated diseases.
PIPELINE
Our precision approach builds on integrated scientific insights – powered by our proprietary data analytics platform – to drive smarter therapeutic development.
science
We foster a culture where teams elevate, challenge, and nurture each other, living our values while driving our mission forward.
careers
January 9, 2026 Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 7, 2026 Alumis Announces Pricing of Upsized Public Offering of Common Stock
January 6, 2026 Alumis Announces Proposed Public Offering of Common Stock
More News
